NCT02835521

Brief Summary

Introduction; reception must be understood as the offered attention within the relationship between a healthcare worker and the patient, including attitudes of inclusion, hearing, valorization of complains and identification of needs, being these individual collective. As a part of this process, communication is a primary and indispensable toll through which the healthcare team and the patient interchange information. Objective: to evaluate the influence of perception of patients suffering of knee osteoarthritis over fear, catastrophizing of pain and effectiveness, related to intra-articular injection od corticosteroids. Material and method: it will be performed a prospective, controlled and randomized study eith a blind evaluator on patients with symptomatic knee osteoarthritis submitted to joint injection. A hundred patients suffering of symptomatic knee osteoarthritis coming from the outpatient area of Rheumatology Division of Federal University of Sao Paulo (UNIFESP) will be evaluated, 50 belonging to the intervention group (reception) and 50 to a control group.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4 knee-osteoarthritis

Timeline
Completed

Started Aug 2016

Shorter than P25 for phase_4 knee-osteoarthritis

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 11, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 18, 2016

Completed
14 days until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

July 18, 2016

Status Verified

July 1, 2016

Enrollment Period

6 months

First QC Date

July 11, 2016

Last Update Submit

July 13, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change on pain

    Pain will be evaluated with an visual analogue scale

    baseline, after 1, 4 and 12 weeks

Secondary Outcomes (3)

  • Change on functional capacity

    baseline, after 1, 4 and 12 weeks

  • Change on Catastrophizing

    baseline, after 1, 4 and 12 weeks

  • Change on functional capacity

    baseline, after 1, 4 and 12 weeks

Study Arms (2)

Intervention Group

EXPERIMENTAL

Patients will receive the reception treatment before the joint injection

Procedure: ReceptionDrug: Joint injection with triamcinolone hexacetonide

Control Group

ACTIVE COMPARATOR

patient will receive a joint injection

Drug: Joint injection with triamcinolone hexacetonide

Interventions

ReceptionPROCEDURE
Intervention Group

joint injection with corticosteroids

Control GroupIntervention Group

Eligibility Criteria

Age50 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • knee osteoarthritis according to american college of rheumatology criteria
  • no previous experience of joint injection
  • stable use of drugs for osteoarthritis treatment for at least 3 months
  • stable dose of corticosteroids, non hormonal anti-inflammatory and analgesics in the previous month
  • pain on knee between 3 and 7 in the visual analogue scale
  • signe the informed consent term
  • radiologic classification between 1-3 (kellgren and Lawrence classification)

You may not qualify if:

  • joint disease of different etiology
  • coagulation alteration
  • non treated fibromyalgia
  • litigation
  • diabetes mellitus and systemic arterial hypertension out of control
  • allergy of lidocaine or triamcinolone hexacetonide

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Injections, Intra-Articulartriamcinolone hexacetonide

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

InjectionsDrug Administration RoutesDrug TherapyTherapeutics

Central Study Contacts

Sandra R Toffolo, Msc nurse

CONTACT

Rita NV Furtado, PhD MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 11, 2016

First Posted

July 18, 2016

Study Start

August 1, 2016

Primary Completion

February 1, 2017

Study Completion

July 1, 2017

Last Updated

July 18, 2016

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share